



NON SELF-INACTIVATING, EXPRESSION TARGETED  
RETROVIRAL VECTORS

RELATED APPLICATIONS

This application is a continuation-in-part of  
5 International Application No. PCT/EP95/03445, filed  
September 1, 1995, which claims priority to Danish  
Application No. 1017/94, filed September 2, 1994.

BACKGROUND OF THE INVENTION

The use of retroviral vectors for gene therapy has  
10 received much attention and currently is the method of  
choice for the transferral of therapeutic genes in a  
variety of approved protocols both in the USA and in Europe  
(Kotani et al., Human Gene Therapy 5:19-28 (1994)).  
However most of these protocols require that the infection  
15 of target cells with the retroviral vector carrying the  
therapeutic gene occurs *in vitro*, and successfully infected  
cells are then returned to the affected individual  
(Rosenberg et al., Hum. Gene Ther. 3:75-90 (1992); for a  
review see Anderson, W.F., Science 256:808-813 (1992)).  
20 Such *ex vivo* gene therapy protocols are ideal for  
correction of medical conditions in which the target cell  
population can be easily isolated (e.g. lymphocytes).  
Additionally the *ex vivo* infection of target cells allows  
the administration of large quantities of concentrated  
25 virus which can be rigorously safety tested before use.

Unfortunately, only a fraction of the possible  
applications for gene therapy involve target cells that can  
be easily isolated, cultured and then reintroduced.  
Additionally, the complex technology and associated high  
30 costs of *ex vivo* gene therapy effectively preclude its

08808827-022097

disseminated use world-wide. Future facile and cost-effective gene therapy will require an *in vivo* approach in which the viral vector, or cells producing the viral vector, are directly administered to the patient in the form of an injection or simple implantation of retroviral vector producing cells.

This kind of *in vivo* approach, of course, introduces a variety of new problems. First of all, and above all, safety considerations have to be addressed. Virus will be produced, possibly from an implantation of virus producing cells, and there will be no opportunity to precheck the produced virus. It is important to be aware of the finite risk involved in the use of such systems, as well as trying to produce new systems that minimize this risk.

Retroviral vector systems consist of two components (Fig. 1):

1) the retroviral vector itself is a modified retrovirus (vector plasmid) in which the genes encoding for the viral proteins have been replaced by therapeutic genes and marker genes to be transferred to the target cell. Since the replacement of the genes encoding for the viral proteins effectively cripples the virus it must be rescued by the second component in the system which provides the missing viral proteins to the modified retrovirus.

The second component is:

2) a cell line that produces large quantities of the viral proteins, however lacks the ability to produce replication competent virus. This cell line is known as the packaging cell line and consists of a cell line transfected with a second plasmid carrying the genes enabling the modified retroviral vector to be packaged.

To generate the packaged vector, the vector plasmid is transfected into the packaging cell line. Under these conditions the modified retroviral genome including the inserted therapeutic and marker genes is transcribed from the vector plasmid and packaged into the modified retroviral particles (recombinant viral particles). This recombinant virus is then used to infect target cells in which the vector genome and any carried marker or therapeutic genes becomes integrated into the target cell's DNA. A cell infected with such a recombinant viral particle cannot produce new vector virus since no viral proteins are present in these cells. However the DNA of the vector carrying the therapeutic and marker genes is integrated in the cell's DNA and can now be expressed in the infected cell.

The essentially random integration of the proviral form of the retroviral genome into the genome of the infected cell (Varmus, *Science* 240:1427-1435 (1988)) led to the identification of a number of cellular proto-oncogenes by virtue of their insertional activation (Varmus, *Science* 240:1427-1435 (1988); van Lohuizen and Berns, *Biochim. Biophys. Acta*, 1032:213-235 (1990)). The possibility that a similar mechanism may cause cancers in patients treated with retroviral vectors carrying therapeutic genes intended to treat other pre-existent medical conditions has posed a recurring ethical problem. Most researchers would agree that the probability of a replication defective retroviral vector, such as all those currently used, integrating into or near a cellular gene involving in controlling cell proliferation is vanishingly small. However it is generally also assumed that the explosive expansion of a population of replication competent retrovirus from a single infection event, will eventually provide enough integration events to make such a phenotypic integration a very real possibility.

08808827.022897  
68220.2880880

5

10

20

35

5  
10  
15  
20

25

## 30

The present invention relates to retroviral vectors including a vector which undergoes promoter conversion (ProCon vectors such as, for example, the BAG vector). The

vector system is useful as a gene transfer vehicle for targeted gene therapy.

In particular, the present invention relates to a retroviral vector which is capable of undergoing promoter  
5 conversion comprising a 5' long terminal repeat (LTR) region of the structure U3-R-U5; one or more sequences selected from coding and non-coding sequences; and a 3' LTR region comprising a completely or partially deleted U3 region wherein said deleted U3 region is replaced by a  
10 polylinker sequence, followed by the R and U5 region. The LTR regions can be selected from at least one element of, for example, Murine Leukaemia Virus, Mouse Mammary Tumor Virus, Murine Sarcoma Virus, Simian Immunodeficiency Virus, Human Immunodeficiency Virus, Human T Cell Leukaemia Virus,  
15 Feline Immunodeficiency Virus, Feline Leukaemia Virus, Bovine Leukaemia Virus, and Mason-Pfizer-Monkey Virus.

In one embodiment, the polylinker sequence of the retroviral vector of the present invention comprises at least one unique restriction site. In another embodiment,  
20 the polylinker sequence comprises at least one insertion of a heterologous DNA fragment (e.g., regulatory elements and promoters). In a particular embodiment of the present invention, the regulatory elements and promoters of the heterologous DNA are target cell specific in their  
25 expression. In addition, the regulatory elements and promoters of the retroviral vector can regulate the expression of at least one of the coding sequences of the retroviral vector. The regulatory elements can also be regulatable by transacting molecules. In another  
30 embodiment, the heterologous DNA is DNA homologous to one or more cellular sequences or a part thereof.

The coding sequences of the retroviral vector of the present invention can be, for example, sequences coding for marker genes, therapeutic genes, antiviral genes, antitumor  
35 genes, and cytokine genes. In another embodiment, at least

08808827 022897  
28808880

5       The present invention also relates to a retroviral  
vector system comprising a retroviral vector which is  
capable of undergoing promoter conversion comprising a 5'  
LTR region of the structure U3-R-U5; one or more sequences  
selected from coding and non-coding sequences; and a 3' LTR  
10 region comprising a completely or partially deleted U3  
region wherein said deleted U3 region is replaced by a  
polylinker comprising regulatory sequences, followed by the  
R and U5 region; and a packaging cell line (e.g., psi-2,  
psi-Crypt, psi-AM, GP+E-86, PA317 and GP+envAM-12)  
15 harboring at least one retroviral or recombinant retroviral  
construct coding for proteins required for said retroviral  
vector to be packaged. In one embodiment, the packaging  
cell line harbors retroviral or recombinant retroviral  
constructs coding for those retroviral proteins which are  
20 not encoded in the retroviral vector.

The present invention also relates to a recombinant  
35 retroviral particle(s) obtained by transfecting a packaging

cell line of a retroviral vector system of the present invention, and culturing the cells under suitable conditions.

The present invention also relates to a retroviral provirus produced by infection of target cells with a recombinant retroviral particle of the present invention whereby the polylinker in the 3' LTR becomes duplicated during the process of reverse transcription in the target cell and appears in the 5' LTR as well as in the 3' LTR of the resulting provirus.

The present invention also relates to mRNA of the retroviral provirus of the present invention. In addition, the invention relates to RNA of a retroviral vector of the present invention. The present invention also relates to a pharmaceutical composition containing a therapeutically effective amount of a recombinant retroviral particle of the present invention.

#### BRIEF DESCRIPTION OF THE FIGURES

Fig. 1 is a graphic representation of a retroviral vector system.

Fig. 2 is a graphic representation of reverse transcription of the retroviral genome.

Fig. 3 is a graphic representation of the ProCon principle.

Fig. 4 are the primers used to construct the modified BAG vector.

Fig. 5 is a graphic representation of construction of plasmid pSmaU3del.

Fig. 6 is a graphic representation of construction of plasmid pCON6.

Fig. 7 are the primers used to construct pMMTVgal.

Fig. 8 is a graphic representation of construction of the plasmid pMMTV-BAG.

Fig. 9 are the primers used to construct pWAPBAG.

08808827.022897

a

a

a

A(SEQ ID NO:1), B(SEQ ID NO:2), and C(SEQ ID NO:3)

D(SEQ ID NO:4), and E(SEQ ID NO:5)

F(SEQ ID NO:6) and G(SEQ ID NO:7)



Fig. 10 is the plasmid pWAPBAG.

Fig. 11 is a graphic representation of a ProCon vector carrying the promoter region from a mouse mammary tumor (MMTV) and the results of PCR analysis of DNA, prepared from clones infected with the vector, using a MLV probe.

Fig. 12 is a graphic representation of a ProCon vector carrying the promoter region from a mouse mammary tumor (MMTV) and the results of PCR analysis of DNA, prepared from clones infected with the vector, using a MMTV probe.

Fig. 13 is a graph of  $\beta$ -galactosidase expression in NIH and EF43 cells infected with MMTV and WAP ProCon vectors.

Fig. 14 is a graph of  $\beta$ -galactosidase expression in primary mammary glands cells from a pregnant mouse infected with MMTV and WAP ProCon vectors.

Fig. 15 is a graph of  $\beta$ -galactosidase expression after virus injection into mammary gland and the skin of a pregnant Balb/c mouse.

Fig. 16 is a graph of  $\beta$ -galactosidase expression in infected mammary tumor cells.

Fig. 17 is a graphic representation of targeted integration of a retroviral vector by homologous recombination.

#### DETAILED DESCRIPTION OF THE INVENTION

The object of the present invention is the construction of a novel retroviral vector which can be used as a safe gene transfer vehicle for targeted gene therapy with a reduced probability to undergo recombination with the packaging construct. This novel vector carries heterologous promoter and/or regulatory elements in the 3'LTR which, after infection become duplicated and translocated to the 5'LTR in the target cell, eventually controlling expression of marker/therapeutic genes, not directly linked to the promoter, but rather inserted into

08808827 "022897  
682220 "288880

the body of the vector. This vector does not undergo self-inactivation - but instead promoter exchange, giving rise to the name ProCon for Promoter Conversion.

Since Promoter Conversion does not result in  
5 Self-Inactivation, the retroviral vector will be transcriptionally active in the target cell. However both LTRs will consist to a large extent of heterologous promoter/enhancer sequences in the target cell. This will  
10 reduce the likelihood of the integrated vector in the target cell being subject to the same inactivation over long periods as has been described for conventional vectors (Xu et al., *Virology* 171:331-341 (1989)) and also will  
15 reduce the chance of recombination with endogenous retroviral sequences to generate potentially pathogenic replication competent virus, increasing the safety of the system.

In this invention the 5'LTR of the retroviral vector construct is not modified, and expression of the viral vector in the packaging cells is driven by the normal  
20 retroviral U3 promoter. Normal retroviral polyadenylation is allowed, and no heterologous polyadenylation signals are included in the 3'LTR. This is important for the development of *in vivo* gene therapy strategies, since the normal physiological regulation of the virus, through the  
25 normal viral promoter, and possibly also involving the normal viral control of polyadenylation, will prevail over long periods *in vivo* whilst the packaging cells are producing recombinant virus.

A further modification of this novel retroviral vector  
30 foresees the inclusion of cellular sequences instead of the heterologous promoter and/or regulatory elements. This should allow higher selectivity for site specific recombination with cellular sequences to target the integration of retroviral vectors to particular sites in  
35 the host cell genome (Saller, R.M., "Design von Locus- und

08808827 2880880

Gewebespezifischen Retroviralen Vektoren Ruer Eine In Vivo  
Gentherapie, Doctoral thesis, Ludwigs-Maximilians  
University Munich, Germany, (1994)).

To achieve the foregoing and other objects, the  
5 invention provides a retroviral vector undergoing promoter  
conversion comprising a 5'LTR region of the structure U3-R-  
US; one or more sequences selected from coding and  
non-coding sequences; and a 3'LTR region comprising a  
completely or partially deleted U3 region wherein said  
10 deleted U3 region is replaced by a polylinker sequence,  
followed by the R and U5 region.

Said polylinker sequence carries at least one unique  
restriction site and contains preferably at least one  
insertion of a heterologous DNA fragment. Said  
15 heterologous DNA fragment is preferably selected of  
regulatory elements and promoters, preferably being target  
cell specific in their expression, but may also be a DNA  
fragment with no regulatory function.

Said heterologous DNA fragment is preferably  
20 homologous to one or more cellular sequences. The  
regulatory elements and promoters are preferably  
regulatable by transacting molecules.

Further objects, features and advantages will be  
apparent from the following description of preferred  
25 embodiments of the invention.

The target cell specific regulatory elements and  
promoters are selected from one or more elements of the  
group consisting of Whey Acidic Protein (WAP), Mouse  
Mammary Tumor Virus (MMTV),  $\beta$ -lactoglobulin and casein  
30 specific regulatory elements and promoters, pancreas  
specific regulatory elements and promoters including  
carbonic anhydrase II and  $\beta$ -glucokinase regulatory elements  
and promoters, lymphocyte specific regulatory elements and  
promoters including immunoglobulin and MMTV lymphocytic  
35 specific regulatory elements and promoters and MMTV

08303327.022397

specific regulatory elements and promoters conferring responsiveness to glucocorticoid hormones or directing expression to the mammary gland. Said regulatory elements and promoters regulate preferably the expression of at least one of the coding sequences of said retroviral vector. The LTR regions are selected from at least one element of the group consisting of LTRs of Murine Leukaemia Virus (MLV), Mouse Mammary Tumor Virus (MMTV), Murine Sarcoma Virus (MSV), Simian Immunodeficiency Virus (SIV), Human Immunodeficiency Virus (HIV), Human T-cell Leukemia Virus (HTLV), Feline Immunodeficiency Virus (FIV), Feline Leukemia Virus (FELV), Bovine Leukemia Virus (BLV) and Mason-Pfizer-Monkey virus (MPMV).

The retroviral vector is based preferably either on a BAG vector (Price et al., *Proc. Natl. Acad. Sci. USA* 84:156-160 (1987)) or an LXS vector (Miller and Rosman, *Biotechniques* 7:980-990 (1989)).

The coding sequence is preferably selected from one or more elements of the group consisting of marker genes, therapeutic genes, antiviral genes, antitumor genes, and cytokine genes.

Said marker and therapeutic genes are preferably selected from one or more elements of the group consisting of  $\beta$ -galactosidase gene, neomycin gene, Herpes Simplex Virus thymidine kinase gene, puromycin gene, cytosine deaminase gene, hygromycin gene, secreted alkaline phosphatase gene, guanine phosphoribosyl transferase (gpt) gene, alcohol dehydrogenase gene and hypoxanthine phosphoribosyl transferase (HPRT) gene.

Another embodiment of the invention envisages the alteration or partial deletion of at least one retroviral sequence required for integration of retroviruses.

In a further embodiment of the invention a retroviral vector system is provided comprising a retroviral vector as described above as a first component and a packaging cell

08808827 022897

line harboring at least one retroviral or recombinant retroviral construct coding for proteins required for said retroviral vector to be packaged.

The packaging cell line harbors retroviral or recombinant retroviral constructs coding for those retroviral proteins which are not encoded in said retroviral vector. The packaging cell line is preferably selected from an element of the group consisting of psi-2, psi-Crypt, psi-AM, GP+E-86, PA317 and GP+envAM-12, or of any of these supertransfected with recombinant constructs allowing expression of surface proteins from other enveloped viruses.

Another embodiment of the invention involves the use of a packaging cell line harboring a recombinant retroviral construct defective in integrase function.

After introducing the retroviral vector of the invention as described above in a retroviral packaging cell line and infection of a target cell, as described above, a retroviral provirus is provided wherein said polylinker and  
20 any sequences inserted in said polylinker in the 3'LTR become duplicated during the process of reverse transcription in the infected target cell and appear in the 5'LTR as well as in the 3'LTR of the resulting provirus.

The invention includes also mRNA of a retroviral provirus according to the invention and any RNA resulting from a retroviral vector according to the invention.

A further embodiment of the invention provides non-therapeutical method for introducing homologous and/or heterologous nucleotide sequences into human or animal cells *in vitro* and *in vivo* comprising transfecting a packaging cell line of a retroviral vector system according to the invention with a retroviral vector according to the invention and infecting a target cell population with recombinant retroviruses produced by the packaging cell line. The nucleotide sequences are selected from one or

The retroviral vector, the retroviral vector system

for targeted integration in homologous cellular sequences.

## PROMOTER CONVERSION

The present invention uses the principle of promoter conversion typical for retroviruses.

The retroviral genome consists of an RNA molecule with the structure R-U5-gag-pol-env-U3-R (Fig. 2). During the process of reverse transcription, the U5 region is duplicated and placed at the right hand end of the generated DNA molecule, while the U3 region is duplicated and placed at the left hand end of the generated DNA molecule (Fig. 2). The resulting structure U3-R-U5 is called LTR (Long Terminal Repeat) and is thus identical and repeated at both ends of the DNA structure or provirus (Varmus, *Science* 240:1427-1435 (1988)). The U3 region at the left hand end of the provirus harbors the promoter (see below). This promoter drives the synthesis of an RNA transcript initiating at the boundary between the left hand U3 and R regions and terminating at the boundary between the right hand R and U5 region (Fig. 2). This RNA is packaged into retroviral particles and transported into the target cell to be infected. In the target cell the RNA genome is again reverse transcribed as described above.

According to the invention, a retroviral vector is constructed in which the right-hand U3 region is altered (Fig. 3), but the normal left-hand U3 structure is

maintained (Fig. 3); the vector can be normally transcribed into RNA utilizing the normal retroviral promoter located within the left-hand U3 region (Fig. 3). However the generated RNA will only contain the altered right-hand U3 structure. In the infected target cell, after reverse transcription, this altered U3 structure will be placed at both ends of the retroviral structure (Fig. 3).

If the altered region carries a polylinker (see below) instead of the U3 region then any promoter, including those directing tissue specific expression such as the WAP promoter (see below) can be easily inserted. This promoter will then be utilized exclusively in the target cell for expression of linked genes carried by the retroviral vector. Alternatively or additionally, DNA segments homologous to one or more cellular sequences can be inserted into the polylinker for the purposes of gene targeting, by homologous recombination (see below).

According to the invention, the term "polylinker" is used for a short stretch of artificially synthesized DNA which carries a number of unique restriction sites allowing the easy insertion of any promoter or DNA segment. The term "heterologous" is used for any combination of DNA sequences that is not normally found intimately associated in nature.

Gene expression is regulated by promoters. In the absence of promoter function a gene will not be expressed. The normal MLV retroviral promoter is fairly unselective in that it is active in most cell types (Majors, *Curr. Topics. In Micro. Immunol.* 157:49-92 (1990)). However a number of promoters exist that show activity only in very specific cell types. Such tissue-specific promoters will be the ideal candidates for the regulation of gene expression in retroviral vectors, limiting expression of the therapeutic genes to specific target cells.

The retroviral promoter structure is carried within the U3 region of the LTR. LTRs carry signals that allow them to integrate into the genome of the target cell. The integration of retroviral proviruses can also contribute to pathogenic changes (van Lohuizen and Berns, *Biochim. Biophys. Acta*, 1032:213-235 (1990)). In one embodiment of the invention ProCon vectors can carry modified LTRs that no longer carry the signals required for integration. Again this increases the potential safety of these vector systems.



[illegible]

5 version of the retroviral genome into the target cell is a  
major <sup>advantage</sup> ~~advance~~ to the use of retroviruses as vectors when  
compared to other viruses such as adenoviruses, since it  
allows long term stable expression of transferred genes.  
However, the random nature of this integration event also  
10 poses a major disadvantage to the use of retroviral vectors  
since it raises the possibility of insertional  
(in)activation of cellular tumor suppressor genes or  
proto-oncogenes and thus tumor induction (van Lohuizen and  
Berns, *Biochim. Biophys. Acta*, 1032:213-235 (1990)).

15 Homologous recombination has been successfully used to  
target the integration of transfected or microinjected DNA  
to specific DNA loci and is routinely used in the  
construction of "knock-out" transgenic mice or animals  
(reviewed in Capecchi, *Science* 244:1288-1292 (1989);  
20 Bradley et al., *Biotechnology* 10:534-539 (1992); Morrow and  
Kucherlapati, *Current Opinion in Biotechnology* 4:577-582  
(1993)). Unfortunately, the efficiency of DNA transfer by  
such purely physical methods is extremely low. In  
contrast, retroviral mediated gene transfer is very  
25 efficient, almost 100% of a population of cells being  
infectable. A combination of retroviral gene transfer with  
homologous recombination should allow the construction of  
an ideal system for locus targeted integration.

We have investigated the feasibility of introducing  
30 long homologous pieces of DNA into retroviral vectors in  
different locations to promote integration by homologous  
recombination (Saller, R.M., "Design von Locus- und  
Gewebespezifischen Retroviralen Vektoren fuer Eine *In Vivo*  
Gentherapie, Doctoral thesis, Ludwigs-Maximilians  
35 University Munich, Germany, (1994)). Both gene conversion

and homologous recombination have been evaluated. Using a cell line carrying a single copy of the HSV-tk gene as a target, we have been able to disrupt the target at frequencies 15 fold higher than previously reported by others (Ellis and Bernstein, *Mol. Cell. Biol.* 9:1621-1627 (1989)). Cloning of the recombined fragments of DNA has revealed the presence of both target tk sequence and retroviral vector (Saller, R.M., "Design von Locus- und Gewebespezifischen Retroviralen Vektoren Ruer Eine *In Vivo* Gentherapie, Doctoral thesis, Ludwigs-Maximilians University Munich, Germany, (1994)).

For targeted integration, DNA segments homologous to cellular sequences are inserted into the polylinker of the ProCon vectors. After infection of the target cell and reverse transcription, these sequences will appear at the 5' terminal end of the provirus. Terminal homologies have been shown to favor homologous recombination (Bradley, *Curr. Opin. Biotechnol* 2:823-829 (1991)) to isogenic cellular sequences (Bradley, *Curr. Opin. Biotechnol* 2:823-829 (1991)). Infection of target cells which carry mutated versions of the homologous sequence should result in the recombination and thus repair of the mutated sequence. Either just the homologous sequences will recombine into the cellular genome, or the complete vector will be inserted (Saller, R.M., "Design von Locus- und Gewebespezifischen Retroviralen Vektoren Ruer Eine *In Vivo* Gentherapie, Doctoral thesis, Ludwigs-Maximilians University Munich, Germany, (1994)). Not only has this vector class potential for use in gene repair, it can also be utilized to direct the integration of retroviral vectors carrying therapeutic genes to specific loci in the genome which are known not to harbor active genes. This will reduce considerably the possibility of insertional activation or inactivation as described above, and will

08000027 022297

thus contribute to the safety of the use of retroviral vectors.

The recombinant DNA methods employed in practicing the present invention are standard procedures, well known to those skilled in the art, and described in detail, for example, in "Molecular Cloning" (Sambrook et al., *Molecular Cloning*, Cold Spring Harbor Laboratory Press, New York, USA, (1989) and in "A Practical Guide to Molecular Cloning"; Perbal, B., "A Practical Guide to Molecular Cloning, John Wiley & Sons, 1984)).

The following examples will illustrate the invention further. These examples are however in no way intended to limit the scope of the present invention as obvious modifications will be apparent, and still other modifications and substitutions will be apparent to anyone skilled in the art.

#### EXAMPLE 1

Mammary gland specific expression after infection with ProCon Vectors carrying mammary specific promoters.

#### 20 DELETION OF THE U3 REGION AND INSERTION OF A POLYLINKER

In the murine leukemia virus (MLV) retroviral vector known as BAG (Price et al., *Proc. Natl. Acad. Sci. USA* 84:156-160 (1987))  $\beta$ -galactosidase gene is driven by the promiscuous (i.e., non-tissue specific) MLV promoter in the U3 region of the LTR (Fig. 3). According to the present invention a derivative of the BAG vector has been constructed in which the MLV promoter (U3) located within the 3'LTR, except the inverted repeat, has been deleted by PCR and replaced by a polylinker. The BAG vector lacking the U3 is expressed from the MLV promoter (U3) within the 5'LTR when introduced into a packaging cells line. As a result of the rearrangements occurring the retroviral genome during its life cycle, following infection of its

08808827.022897

target cell, the polylinker will be duplicated at both ends of the retroviral genome as described in WO-A1-9607748.

Thereby a retroviral vector can be constructed in which the expression of the  $\beta$ -galactosidase gene of BAG will be

5 controlled by any heterologous promoter inserted into the polylinker.

As a template for PCR we used pBAGN as plasmid carrying a derivative of the BAG construct carrying only one LTR, created by an NheI digest of the original pBAG  
10 followed by a self-ligation of the 7018bp fragment.

The 3' end of primer A is complementary to the R-region of the LTR (Fig. 4). The 5'-extension contains an artificial (art) polylinker and an artificial inverted repeat (IR(art.)). Primer B is complementary to the U5  
15 region of the LTR (Fig. 4). After 35 cycles of annealing at 47°C and extension at 60°C, a 140 bp product was obtained, which was used as a template for the second PCR. In this reaction a Clal site and an artificial (+)PBS was added 5' of the IR-region using primer C (Fig. 4) in  
20 combination with primer B. Annealing was carried out at 53°C and extension at 72°C. After 35 cycles a 163 bp product was obtained, which was digested with Clal and SmaI and ligated to a 2722bp Clal/SmaI fragment of pSmaI (Fig. 5). The resulting plasmid pSmaU3del (2792bp) was  
25 linearized by a SmaI digest and ligated to a 3677bp SmaI fragment of pBAGN (Fig. 6) to give the plasmid pBAGNU3del (6369bp). Deletion of the U3 region was confirmed by sequencing from the Clal-site into the U5-region using pSmaU3del as template. A Clal/SpeI (322bp) fragment  
30 containing the U3 deleted LTR was ligated to a Clal/NheI fragment of pBAGNB (created by self ligation of a 3946bp fragment of pBAGN) to give the plasmid pCON6 (4097bp) (Fig. 6). This plasmid carrying a full U3-minus retroviral vector was used as a basis for further cloning.

080827 02297  
268220 288080

5 promoter, including a region that confers responsiveness to glucocorticoid hormones and a region containing an element that directs expression to the mammary gland; the Whey Acidic Protein (WAP) promoter. This promoter controls the expression of WAP so that it is only produced in the  
10 mammary glands of pregnant and lactating rodents.

The Mouse Mammary Tumour Virus (MMTV) U3-Region (mtv-2) without the inverted repeats includes a region that confers responsiveness to glucocorticoid hormones and a region containing an element that directs expression to the mammary gland.

20        The 3' end of primer D is complementary of the 5' end of MMTV U3 region and carries a SacII site in its 5' extension (Fig. 7). The 3' end of primer E is complementary to the 3' end of the MMTV U3 region and has a MluI site in its 5' extension (Fig. 7).

After 35 cycles of annealing at 49°C and extension at 72°C, a 1229bp product was obtained, digested with SacII and MluI and ligated to the SacII/MluI digested vector pCON6. The resulting plasmid p125.6 (5305bp) (Fig. 8) was digested with XbaI and HindIII and the 4187 bp fragment ligated to the 4190bp fragment of pBAGN containing the  $\beta$ -galactosidase gene to give the plasmid pMMTV-BAG (8377bp) (Fig. 8) in which the  $\beta$ -galactosidase gene is under the

CLONING OF THE WHEY ACIDIC PROTEIN (WAP) PROMOTER REGION  
ENCOMPASSING THE PROXIMAL 445 BP OF THE WAP PROMOTER

A plasmid, pWAPBAG containing the  $\beta$ -galactosidase gene under transcriptional control of the proximal 445 bp's of the WAP promoter was prepared by amplification of a sequence comprising the proximal 445 bp's of the WAP

The control of the  $\beta$ -galactosidase gene expression by promoters inserted into the polylinker has been validated by infection studies using the constructed MMTV and WAP retroviral vectors to infect various cells.

30 To produce retroviral vector particles, the MMTV and WAP ProCon vectors have been transfected into the packaging cell line GP+E86 (Markowitz et al., *J. Virol.* 62:1120-1124 (1988)). After selection for neomycin resistance, which is encoded by the vector, stable populations and clones of

recombinant ProCon virus producing cells were obtained. Virus containing supernatant from these populations was used to infect a mouse mammary cell line EF43 (Gunzburg et al., *Carcinogenesis* 9:1849-1856 (1988)) as well as a mouse  
5 fibroblast cell line (Jainchill et al., *J. Virol* 4:549-553 (1969)). Four days after infection, the target cells were lysed and quantitative  $\beta$ -galactosidase assay revealed no expression in either cell type infected by the WAP carrying ProCon vectors and good expression in both cell types from  
10 the MMTV carrying ProCon vector (Fig. 13). This result is in accordance with the WAP promoter only functioning *in vivo* during late pregnancy and lactation and not in most simple *in vitro* mammary cell culture systems as represented by the EF43 cells. To investigate whether the WAP carrying  
15 ProCon vectors would be active in a complex primary mammary derived cell culture system, primary organoids from 8-10 day pregnant mice (Fig. 14) or from mammary tumors (Fig. 16) were taken into culture and infected with the supernatant from the same stably transfected population of  
20 transfected cell lines. Both ProCon vectors carrying the WAP and the MMTV promoter fragments were active in these primary cells (Fig. 14) and mammary tumor derived cells (Fig. 16) as demonstrated by  $\beta$ -galactosidase activity.

To investigate whether the WAP and MMTV carrying  
25 ProCon vectors were active *in vivo* and whether the expression of  $\beta$ -galactosidase was limited to the mammary gland *in vivo*, recombinant ProCon virus containing medium was injected *in situ* into the mammary glands or skin of  
8-10 day pregnant mice. Five days later, the mice were  
30 sacrificed, cell extracts prepared and a  $\beta$ -galactosidase assay performed. Both the WAP and MMTV fragment carrying ProCon vectors were expressed only in the pregnant mammary gland and not in the skin (cf M and S in Fig. 15). Thus *in vivo* the regulatory elements from both promoters limit  
35 expression to the mammary gland whereas *in vitro* the

These ProCon vectors carrying tissues specific-promoters and regulatory elements will be useful for

5 directing the expression of therapeutic genes to predefined cell types, tissues and organs. Potential therapeutic genes include melittin, which has anti-HIV and anti-tumor effects, and genes which prime cells for death including the thymidine kinase, guanine phosphoribosyltransferase and  
10 cytosine deaminase genes, cytochrome P450, as well as genes involved in cell cycle regulation such as SDI/WAF1/CIP-1.

## EXAMPLE 2

Validation of promoter conversion in cells infected with a ProCon vector that originally carried the MMTV promoter in the 3'LTR:

A ProCon vector carrying the promoter region from mouse mammary tumor virus (MMTV) was transfected into a packaging cell line and the resultant recombinant vector particles used to infect an established human bladder carcinoma cell line (EJ). Infected cell clones were selected in medium carrying the neomycin analog G418 (since the vector carries a neomycin resistance gene driven from an internal SV40 promoter). DNA was prepared from one of the infected clones and nontransfected parental EJ cells and used for Polymerase Chain Reactions (PCR). The PCRs were performed using one of two primers that specifically recognize and bind to MMTV sequences (A, B in Figs. 11 & 12) or the MLV R region (C in Fig. 11) of the LTR together with a primer located within the marker gene (Figs. 11 & 12). Since the marker gene primer is only located downstream of the MMTV (or MLV R region) sequence if promoter conversion has occurred, a positive PCR signal obtained with the MMTV primers in combination with the marker gene



primer is indicative of this. In Fig. 4 the PCR products using primers A, B or C are shown after hybridization to a labelled fragment from the MLV sequence, verifying that all three PCR products are of MLV origin. The size of the fragments verifies that promoter conversion has occurred. Fig. 5 shows the PCR products using primer A or B and hybridized to an MMTV specific probe, again verifying that promoter conversion has occurred.

### EXAMPLE 3

#### 10 Construction of ProCon Vectors for targeted integration:

Using the same BAG vector described in Example 1 above, a retroviral vector can be constructed in which a DNA sequence with homology to a cellular sequence can be inserted into the LTR. The resulting vector can be used to target the integration of either the homologous sequence inserted into the vector or the whole or part of the vectors into the homologous sequence present in the host cell genome.

According to the principle set forth above, a fragment of the thymidine kinase (tk) gene of herpes simplex virus (HSV) has been inserted into the polylinker region of the modified BAG vector (tk mutant in Fig. 17, Saller, R.M., "Design von Locus- und Gewebespezifischen Retroviralen Vektoren Ruer Eine *In Vivo* Gentherapie, Doctoral thesis, Ludwigs-Maximilians University Munich, Germany, (1994)).

A cell line has also been established that has no functional copy of the mammalian tk gene and instead carries one copy of the HSV-tk gene (Saller, R.M., "Design von Locus- und Gewebespezifischen Retroviralen Vektoren Ruer Eine *In Vivo* Gentherapie, Doctoral thesis, Ludwigs-Maximilians University Munich, Germany, (1994)). This cell line has been infected with the tk carrying BAG

08080827 022697

vector and cells that have undergone disruption of the HSV-tk gene have been selected (Fig. 17).

The above examples have illustrated the principles and consequences of the promoter conversion vectors provided by  
5 the present invention.

#### EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention  
10 described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.

08808827-022897